Actelion: Pharmacovigilant

Actelion didn't exactly hit the jackpot when OGS signed the Swiss company up to market its embattled Zavesca in Europe. But the move will cost Actelion little, and highlights that company's emerging status as a product-focused and independent biotech company, and a valuable marketing partner for niche drugs.

There are probably fewer than a dozen specialist Gaucher's disease treatment centers in the whole of Europe, and so it seems curious at first that Oxford GlycoSciences PLC (OGS) would need a European partner, Switzerland's Actelion Pharmaceuticals Ltd., for help in marketing oral miglustat (Zavesca, formerly known as Vevesca), its treatment for the lysosomal storage disorder [See Deal].

But Actelion's experience marketing bosentan (Tracleer) worldwide for pulmonary arterial hypertension, and its expertise and established infrastructure in post-approval patient...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo